Research library

A

grade

Orforglipron resulted in statistically significant weight loss in Japanese adults with obesity compared to placebo, but the clinical implications of this weight loss need further investigation.

Mean percentage change in bodyweight was -5.9% with orforglipron 6 mg, -8.7% with 12 mg, and -7.9% with 36 mg, compared with -0.6% with placebo (all p<0.0001).

summary

A

grade

Orforglipron was associated with a significant body weight reduction of -13.5% in adults with a BMI of 27 to less than 30 kg/m² and adiposity-related complications after 72 weeks.

At Week 72, orforglipron 17.2 mg was associated with a mean percent body weight reduction of -13.5% versus placebo at -0.3%, nominal p < 0.001.

summary

D

grade

Not reported in abstract.

summary

D

grade

Not reported in abstract.

summary

D

grade

Not reported in abstract.

summary

A

grade

Patients reported a mean reduction in glycated hemoglobin of 1.6% and a mean weight loss of 4.7 kg, expressing high satisfaction with the treatment.

Patients reduced glycated hemoglobin by 1.6% (SD = 1.3) from a baseline of 8.3%.

summary

A

grade

Orforglipron demonstrated non-inferiority to insulin glargine for cardiovascular safety in adults with type 2 diabetes, but gastrointestinal side effects were common.

HR 0.84; 95% CI 0.59-1.20; p<0.0001 for non-inferiority.

summary

D

grade

Not reported in abstract.

summary

B

grade

Oral Wegovy was associated with greater early weight loss than Foundayo in a matched cohort at 90 days, but the findings should be interpreted with caution due to small sample sizes.

Mean weight change by 90 days was -3.1% with oral Wegovy (n=26) versus +0.4% with Foundayo (n=18), corresponding to a 3.55-percentage-point difference (95% CI, 1.02-6.08; P=0.007).

summary

D

grade

Orforglipron shows a statistically significant reduction in HbA1c and body weight in type 2 diabetes, but the clinical relevance of these findings should be carefully considered.

Pooled HbA1c reduction of −1.14 percentage points versus placebo (95% CI −1.25 to −1.02; I²=0%)

summary

A

grade

Orforglipron shows a mean placebo-adjusted weight reduction of 7.1% to 10.6%, but further research is needed to assess its efficacy for obesity-related comorbidities.

mean 7.1% to 10.6% placebo-adjusted weight reduction with orforglipron

summary

B

grade

Practitioners should consider individual patient ocular risks when prescribing GLP-1 receptor agonists, particularly high-exposure formulations like semaglutide and orforglipron.

Hazard ratios for NAION ranged from 1.29 to 7.64.

summary

A

grade

In obese adults, orforglipron 36 mg shows statistically significant improvements in weight and metabolic outcomes compared to 12 mg, but the clinical significance of these findings requires further investigation.

Percentage body weight change p < 0.00001.

summary

A

grade

Orforglipron was associated with significant reductions in predicted 10-year risks for Type 2 diabetes and cardiovascular disease compared to placebo over 72 weeks, but the clinical relevance of these findings needs further evaluation.

-48.6% to -59.4% relative reduction in T2D risk score vs placebo (-10.5%; p<0.0001; HR-range 0.43-0.55)

summary

D

grade

Orforglipron shows promise in reducing certain metabolic parameters, but its effects on kidney health remain uncertain until further trials specifically address renal outcomes.

Not reported in abstract.

summary

B

grade

The AHA PREVENT equations may offer a more accurate assessment of cardiovascular risk reduction from orforglipron compared to the older PCE, but these findings need validation with real patient data.

For a representative 50-year-old man with T2D at the 36 mg dose, PCE estimated a 10-year RRR of 16.8%, while PREVENT projected an RRR of 31.4%.

summary

C

grade

The study reveals that GLP-1R variants can enhance orforglipron binding, but this does not guarantee effective pharmacological action, highlighting the need for further validation.

G168S exhibited the strongest binding (-117.18 kcal/mol)

summary

B

grade

Orforglipron resulted in a placebo-subtracted weight loss of -12.4% in adults without diabetes, but gastrointestinal side effects were common.

-12.4% placebo-subtracted weight loss for orforglipron (95% CI, -15.1% to -9.7%)

summary

A

grade

Orforglipron showed a high rate of treatment-emergent adverse events in Japanese adults with type 2 diabetes, particularly at higher doses, indicating caution in its use.

339 participants (85%, 95% CI 80·7-87·8) had at least one treatment-emergent adverse event (TEAE).

summary

D

grade

Not reported in abstract.

summary

A

grade

Not reported in abstract.

summary

D

grade

Not reported in abstract.

summary

A

grade

Orforglipron was associated with significant weight loss in older adults with obesity compared to placebo at Week 72, but the clinical relevance of the findings should be carefully considered.

-7.9% weight change with orforglipron 5.5 mg vs placebo at Week 72, n=118, p<0.001.

summary

A

grade

Orforglipron does not appear to increase the risk of drug-induced liver injury compared to other treatments in adults with obesity or type 2 diabetes.

Six (0.1%) orforglipron-treated participants had ALT or AST ≥ 3 × ULN and TBIL ≥ 2 × ULN.

summary

A

grade

Orforglipron showed a mean weight reduction of -11.8% compared to placebo, but evidence certainty was low to moderate.

-11.8% percent body weight reduction for orforglipron compared to placebo.

summary